It’s Time to Evolve Beyond FMTs and Advance LBPs
The FMT era has been productive, but now it’s time to rally together as an industry to accelerate next-generation LBP drug discovery, development and FDA approval.
Evelo Bio Shutdown Follows a Series of Microbiome Therapy Trial Failures
Evelo Biosciences’ vision of using microbes to engage the gut and modulate immune responses remains unrealized. With financing prospects dim and no one willing to take on its assets, Evelo is dissolving its business.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Former Paige.AI CEO Launches Microbiome Profiling Startup
Jona, a New York-based gut microbiome testing startup, emerged from stealth with $5 million in funding. The company's at-home microbiome profiling kit educates users about how the community of microorganisms residing in their gut impacts their overall health. The platform also offers recommendations concerning diet and lifestyle modifications based on users’ personal health goals.
Skin Microbiome and Allergies: Understanding the Role of Microbes in Allergic Skin Conditions
Future research should focus on identifying the interactions between the immune system, microbes, and allergic responses; and exploring potential therapeutic strategies targeting the skin microbiome for allergy management.
Seres’s Bacteria in a Pill Becomes First FDA-Approved Oral Microbiome Therapy
Recurrent Clostridioides difficile infection can be treated with fecal microbiota transplants. FDA approval of Seres Therapeutics’ Vowst makes it the first oral microbiome therapy.
Industrial Scale Microbiome Mining is a New Drug Discovery Toolbox
Within ten years of execution and widespread adoption, most pipelines will be traced to the opportunity of untapped microbes of the earth.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Novome gets $43.5M boost for its engineered microbiome therapies
Novome Biotechnologies — a biotech that CEO Blake Wise says is only company to pursue engineered cell therapy with microbes for the treatment of chronic diseases — raised $43.5 million in Series B funds. The biotech will use the money to advance clinical testing for its lead drug candidate, which seeks to decrease patients' urinary oxalate, as well as advance its pipeline of preclinical genetically engineered microbes.
Takeda ends microbiome alliance with Finch Therapeutics after pipeline review
The agreement termination means that two preclinical microbiome therapy candidates for inflammatory bowel disease will now return to Finch Therapeutics. The biotech company had been collaborating with Takeda Pharmaceutical since 2017.
Persephone rakes in $15M to support country’s biggest cancer microbiome study
Persephone Biosciences, a preclinical biotech focused on microbiome-based medicines, raised $15 million in seed funding on Tuesday. The company will use the money to advance its trial for oncology therapeutics, as well as to continue developing its preventive medicine for infants.
Microbiome biotech Kaleido Biosciences shutters amid cash crunch, drug setbacks
Kaleido Biosciences, formed by Flagship Pioneering as part of a wave of biotech companies developing microbiome therapies, has laid off its entire workforce and is winding down operations. The shutdown follows a strategic review that failed to turn up any deals to support its clinical-stage pipeline.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Sanofi makes another mRNA move with deal for skin microbiome biotech Origimm
Sanofi’s strategy to develop new messenger RNA vaccines is adding another piece. The pharmaceutical giant struck a deal to acquire Origimm Biotechnology, a startup developing therapeutic vaccines to treat skin diseases and infections.
Vedanta Bio guts out microbiome trial win to keep up with field, get BARDA cash
Vedanta Biosciences is developing its microbiome therapy with support from the Biomedical Advanced Research and Development Authority. Under terms of that contract, the positive Phase 2 results in preventing recurrent C. diff infection trigger a $23.8 million payment.
FDA warns Kaleido Bio to test its Covid-19 candidate as a drug, not a medical food
The FDA issued a warning letter to Kaleido Biosciences alleging the company tested its experimental microbiome product in Covid-19 patients without submitting a formal clinical trial application. Kaleido claims the filing was not required because the product is a medical food, but the regulator doesn’t buy that argument.
The precipitous decline of once-promising microbiome startup uBiome
Here's how the San Francisco company went from being an investor darling valued at $600 million to being under investigation by the FBI for its corporate practices.
uBiome appoints general counsel as interim CEO; founders placed on leave
The appointment of John Rakow follows a raid on the company's offices in San Francisco last week connected with an investigation into allegations it had been double billing insurers.